What are the IASP recommendations for the treatment of herpes zoster (shingles) in immunocompromised patients?

Updated: Feb 11, 2021
  • Author: Camila K Janniger, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

IASP recommendations for immunocompromised patients are as follows [1] :

  • Intravenous acyclovir is the therapy of choice for allogeneic hematopoietic stem cell transplant recipients within 4 months of transplantation, hematopoietic stem cell transplant recipients with moderate-to-severe acute or chronic graft versus host disease, or any transplant recipient receiving aggressive antirejection therapy.

  • For less severely immunosuppressed patients, oral therapy with acyclovir, valacyclovir, or famciclovir, coupled with close clinical observation, is a reasonable option.

  • Brivudin is not recommended for patients undergoing chemotherapy with 5-fluoropyrimidines.

  • For highly immunocompromised patients who present with herpes zoster ophthalmicus, intravenous acyclovir and evaluation by an ophthalmologist is recommended.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!